Palexia RP (tapentadol extended release) / Assertio, Collegium Pharma, Grunenthal, J&J 
Welcome,         Profile    Billing    Logout  

6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
2017-000141-52: The effect of tapentadol and oxycodone on the human pain system Effekten af tapentadol og oxycodon på det humane smertenetværk

Ongoing
4
20
Europe
Palexia Depot, OxyContin, Modified-release tablet, Palexia Depot, OxyContin
Asbjørn Mohr Drewes, Grünenthal GmBH
Healthy volunteers - pain, Pain, Diseases [C] - Nervous System Diseases [C10]
 
 
2016-005082-31: Assessment of Tapentadol effects on patients with pain central sensitization using functional MRI Evaluación del efecto de tapentadol en pacientes con dolor por sensibilización central utilizando la resonancia magnética funcional (fMRI)

Ongoing
4
40
Europe
Palexia Retard, Palexia retard, Prolonged-release tablet, Palexia retard 50 mg, Palexia retard 100 mg, Palexia retard 150 mg, Palexia retard 200 mg, Palexia retard 250 mg
MRI Research Unit, Radiology Department. Hospital del Mar., Grunenthal Pharma S.A.
Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Patients suffering from pain due to knee osteoarthritis Pacientes con dolor por artrosis de rodilla, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-001285-23: A comparison of pain relief and effects on respiration from tapentadol and oxycodone after surgical removal of the uterus.

Not yet recruiting
4
90
Europe
Tablet, Modified-release tablet, Capsule, hard, Palexia® 50 mg, Palexia depot®, OxyNorm®, OxyContin®
Oslo University Hospital, Oslo University Hospital
Pain after laparoscopic hysterectomy., Pain after surgical removal of the uterus using a minimal invasive surgical technique., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
 
 
2009-017470-20: An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol hydrochloride, KF5503/42, KF5503/44 or KF5503/45.

Ongoing
3
25
Europe
Tapentadol 50 mg film coated tablet, Tapentadol 50 mg prolonged release tablet, Tapentadol 100 mg prolonged release tablet, Tapentadol 150 mg prolonged release tablet, Tapentadol 200 mg prolonged release tablet, Tapentadol 250 mg prolonged release tablet, CG5503,
Laboratoires Grünenthal
Severe chronic pain
 
 
2022-001358-41: Clinical study to prove that treatment of chronic (non-specific) low back pain with VER-01, a cannabis based medicine, shows benefit compared to treatment with opioids

Not yet recruiting
3
350
Europe
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype, Tilidine and Naloxone (50 mg/4 mg) prolonged-release tablets, Tilidine and Naloxone (100 mg/8 mg) prolonged-release tablets, Tramadol 100 mg prolonged-release tablets, Tramadol 200 mg prolonged-release tablets, Fentanyl 12 micrograms/h transdermal patch, Fentanyl 25 micrograms/h transdermal patch, Fentanyl 50 micrograms/h transdermal patch, Oxycodone 5 mg prolonged-release tablets, Oxycodone 20 mg prolonged-release tablets, Oxycodone & Naloxone (5 mg/2.5 mg) prolonged-release tablets, Oxycodone & Naloxone (20 mg/10 mg) prolonged-release tablets, Hydromorphone 4 mg Prolonged Release tablets, Hydromorphone 8 mg Prolonged Release tablets, Morphine 10 mg prolonged-release tablets, Morphine 20 mg prolonged-release tablets, Tapentadol 50 mg prolonged-release tablets, Tapentadol 100 mg prolonged-release tablets, Buprenorphine 5 µg/h Transdermal Patch, Buprenorphine 15 µg/h Transdermal Patch, Buprenorphine 35 µg/h Transdermal Patch, VER-01, NA, Not Applicable, Oral solution, Prolonged-release tablet, Transdermal patch
Vertanical GmbH, Vertanical GmbH
Chronic non-specific low back pain, Back pain in between the lower edge of the ribs and the lower fold of the buttocks lasting for at least 3 months which has no specific identifiable cause, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2012-003770-11: A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain

Ongoing
2
60
Europe
Palexia Depot, OxyContin, Palexia Depot, OxyContin
C4Pain ApS, Grünenthal GmbH
Osteoarthritic Knee Pain.
 
 

Download Options